Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review.

ABSTRACT:

Objectives

To summarize cost-effectiveness (CE) evidence of sacubitril/valsartan for the treatment of heart failure (HF) patients with reduced ejection fraction (HFrEF). The impact of different modeling approaches and parameters on the CE results is also described.

Methods

We conducted a systematic literature review using multiple databases: Embase^®; MEDLINE^®; MEDLINE^®-In Process; NIHR CRD database including DARE, NHS EED, and HTA databases; and the Cost Effectiveness Analysis registry. We also reviewed HTA countries' websites to identify CE reports of sacubitril/valsartan, published up to 25-July-2021. Articles published in English as full-texts, conference-abstracts, or HTA reports were included.

Results

We included 44 CE models [39

SUBMITTER: Proudfoot C 

PROVIDER: S-EPMC10060315 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature